[%XjIQ%]
Research by Kenanga
OUTPERFORM – TP RM1.12

"Received FDA Approval”

KAREX has received approval from the United States Federal Drug Agency (FDA) to market its new synthetic condoms in the country, in quick succession after the European CE approval. This latest development significantly enhances KAREX’s growth potential,though large orders are more likely to come through in FY26 and beyond as the product gains traction. We maintain our forecasts, TP of RM1.12 and OUTPERFORM call.

Analyst:
Cheow Ming Liang 
[%sIkR%]

$KLSE-KAREX
Research by Kenanga
OUTPERFORM – TP RM1.12

"Received FDA Approval”

KAREX has received approval from the United States Federal Drug Agency (FDA) to market its new synthetic condoms in the country, in quick succession after the European CE approval. This latest development significantly enhances KAREX’s growth potential,though large orders are more likely to come through in FY26 and beyond as the product gains traction. We maintain our forecasts, TP of RM1.12 and OUTPERFORM call.

Analyst:
Cheow Ming Liang 
cheowml@kenanga.com.my